Pcsk 9 Sirna denied as duplicate or overlapping therapy by Cigna?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for pcsk9 sirna are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Pcsk 9 Sirna
## Why Cigna Denies a PCSK9 siRNA Agent as Duplicate Therapy
Cigna's duplicate-therapy denial for a PCSK9 small-interfering RNA (siRNA) agent arises when the claims system identifies that you are also receiving another agent that targets the same biological pathway — most commonly a PCSK9 monoclonal antibody or another PCSK9-directed treatment. Because both drug classes lower LDL by inhibiting PCSK9 activity, Cigna's automated review flags the combination as therapeutically redundant and declines to cover the second agent. This denial reflects a formulary-management rule, not a clinical determination that the combination is harmful.
## Why This Denial Is Appealable
A duplicate-therapy denial is appealable on the grounds that your prescriber has a specific, documented clinical rationale for using this particular agent rather than — or in transition from — the other therapy. ACA §2719 and ERISA §503 apply. If your prescriber is transitioning you from one agent to the other, a brief overlap may be clinically appropriate and can be defended in an appeal. External review is available if the internal appeal fails, generally within 4 months of the denial.
## The Appeal Process and Timeline
1. Clarify which agents triggered the duplicate flag: obtain the denial rationale from Cigna in writing. Confirm which active prescription or claim prompted the duplication determination. 2. Determine the clinical situation: is this a transition (overlap during switch), a combination prescribed intentionally, or an administrative error (a discontinued therapy still appearing active)? 3. File Level 1 internal appeal with a prescriber letter explaining the clinical rationale and, if applicable, confirming discontinuation of the prior agent. 4. Request external review if the internal appeal is denied.
## Documentation to Gather
- Prescriber letter addressing the duplication: explains why the siRNA agent is being used, whether the other PCSK9-directed therapy has been or will be discontinued, and the clinical reasoning for the choice of agent.
- Medication list and discontinuation records: if the other PCSK9 agent is being stopped, a chart note or pharmacy record confirming discontinuation resolves many duplicate-therapy denials administratively.
- Clinical rationale for the specific agent: the prescriber should document any clinical reason — such as dosing schedule, tolerability, or patient-specific factor documented in the chart — that makes the siRNA agent the appropriate choice.
- Cigna's duplicate-therapy policy: request the specific policy section that was applied so the appeal can address it directly.
## Criteria-Mapping Structure
Your appeal should open by acknowledging the duplication flag, then immediately present the clinical resolution: either a confirmed discontinuation date for the other therapy, or a prescriber explanation of the clinical distinction. For each criterion in Cigna's duplicate-therapy exception policy, provide the matching chart fact or prescriber statement. Keep the appeal focused — a clear, concise explanation of why the two agents are not functionally redundant in your specific clinical situation is more persuasive than a lengthy narrative.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →